A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.

ABSTRACT:

Background

Relapsed/refractory small cell lung cancer (SCLC) has a poor prognosis, with no good options. We evaluated a novel combination of topotecan and doxorubicin, providing sequential topoisomerase I and II inhibition, in this setting.

Materials and methods

Adult patients (>19 years) with relapsed/refractory SCLC, who had received at least one prior chemotherapy regimen were eligible. Patients received escalating doses of oral topotecan on days 1-5 of each three week cycle (maximum - 5 cycles). The dosing cohorts were: 0.85 mg/m², 1.05 mg/m², 1.35 mg/m², 1.65 mg/m² and 2.30 mg/m². All patients received weekly doxorubicin 20 mg/m² intravenously starting day 6 of the first cycle and continued weekly for a m

SUBMITTER: Ernani V 

PROVIDER: S-EPMC7315624 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature